Literature DB >> 8932985

IL-1 beta release from cultured bronchial epithelial cells and bronchoalveolar lavage cells from allergic and normal humans following segmental challenge with ragweed.

A T Hastie1, K B Everts, S K Cho, J Zangrilli, J R Shaver, M B Pollice, J E Fish, S P Peters.   

Abstract

This work investigated whether interleukin 1 beta (IL-1 beta) release from epithelial cells is modulated by antigen challenge in vivo, and inflammatory cells in vitro. Bronchial epithelial cells were obtained before and after segmental allergen challenge in allergic and normal individuals, and were cultured with and without autologous bronchoalveolar lavage (BAL) cells. IL-1 beta in culture medium was quantitated by enzyme-linked immunoabsorbent assay (ELISA). Pre-challenge IL-1 beta levels from epithelial cells were similar in allergic (4.4 +/- 0.8 pg/ml, n = 32) and normal (6.8 +/- 1.7 pg/ml, n = 17) subjects. IL-1 beta levels were significantly elevated from epithelium with BAL cell co-culture vs without co-culture in both subject groups (allergic, 13.2 +/- 2.3 pg/ml, P = 0.006; normal: 16.4 +/- 4.0 pg/ml, P = 0.007). Post-challenge IL-1 beta from epithelial cells without BAL cells was increased in both groups, but significant only for allergic subjects (P = 0.003). Post-challenge IL-1 beta from epithelial with BAL cells changed little for allergic subjects (13.8 +/- 2.4 pg/ml), and increased for normal subjects (20.0 +/- 4.8 pg/ml). Decreased production of tumour necrosis factor alpha (TNF-alpha) was observed in allergic subjects (day 1: 447 pg/ml vs day 2: 258 pg/ml). Moreover, pre-challenge release of TNF-alpha and IL-1 beta levels from epithelial + BAL cells correlated well for allergic (r = 0.84) and normal subjects (r = 0.6), but post-challenge release correlated only in normal subjects (r = 0.90). These results indicate that bronchial epithelial cells and BAL cells interact, modulating release of these inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932985     DOI: 10.1006/cyto.1996.0097

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes.

Authors:  Annette T Hastie; Wendy C Moore; Deborah A Meyers; Penny L Vestal; Huashi Li; Stephen P Peters; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2010-04-15       Impact factor: 10.793

2.  Oncostatin M synergises with house dust mite proteases to induce the production of PGE(2) from cultured lung epithelial cells.

Authors:  D A Knight; N Asokananthan; D N Watkins; N L Misso; P J Thompson; G A Stewart
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

3.  Interactions of allergens and irritants in susceptible populations in producing lung dysfunction: implications for future research.

Authors:  A T Hastie; S P Peters
Journal:  Environ Health Perspect       Date:  2001-08       Impact factor: 9.031

Review 4.  Immune Homeostasis in Epithelial Cells: Evidence and Role of Inflammasome Signaling Reviewed.

Authors:  Paul M Peeters; Emiel F Wouters; Niki L Reynaert
Journal:  J Immunol Res       Date:  2015-08-19       Impact factor: 4.818

Review 5.  The inflammasomes, immune guardians at defence barriers.

Authors:  Pablo Palazon-Riquelme; Gloria Lopez-Castejon
Journal:  Immunology       Date:  2018-09-06       Impact factor: 7.397

6.  Toosendanin activates caspase-1 and induces maturation of IL-1β to inhibit type 2 porcine reproductive and respiratory syndrome virus replication via an IFI16-dependent pathway.

Authors:  Mingxin Zhang; Chunni Lu; Lizhan Su; Feixiang Long; Xia Yang; Xiaofeng Guo; Gaopeng Song; Tongqing An; Weisan Chen; Jianxin Chen
Journal:  Vet Res       Date:  2022-07-29       Impact factor: 3.829

7.  Six gene and TH2 signature expression in endobronchial biopsies of participants with asthma.

Authors:  Stephany Sánchez-Ovando; Katherine J Baines; Daniel Barker; Peter A Wark; Jodie L Simpson
Journal:  Immun Inflamm Dis       Date:  2020-01-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.